Entities / Company
HUMIRA.
Czech company
- Reports this week
- 0
- Active events
- 2
- Connections
- 22
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Well supported5 reports1 development inside
-
AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.Well supported3 reports4 developments inside
Earlier this month
-
AbbVie's Humira is losing exclusivity and facing intense competition from Skyrizi and Rinvoq.Some support4 reports
-
AbbVie products are succeeding Humira in the market, while FDA approvals and Fed caution influence market expectations.Well supported4 reports1 development inside
-
AbbVie overcame the loss of Humira exclusivity, leading to a stock rally while Pfizer stock sank.Some support1 report
-
Declining sales of Humira due to biosimilar erosion.Well supported7 reports2 developments inside
-
Eight biosimilars for Humira were launched on October 8, 2026, increasing competition in the market.Some support1 report
One to three months ago
Gone quiet
No new reports in 90+ days-
cAMPfield Therapeutics is seeking alternatives to drugs like Humira, while Blackstone invests in drug development deals.Some support1 report
-
The patent expiry of Humira is weighing on sentiment, influenced by geopolitical uncertainty in the Middle East.Some support2 reports
-
AbbVie, which lost exclusivity for Humira, is facing potential tariffs on pharmaceutical imports from the Trump administration.Speculative2 reports
-
Johnson & Johnson tested nipocalimab against Humira, while Amgen is noted for biosimilar competition in the market for Humira.Some support1 report1 development inside
-
MoonLake Immunotherapeutics' sonelokimab demonstrated superior performance compared to Humira in multiple Psoriasis metrics.Some support2 reports
-
FDA recognized Hadlima as an interchangeable biosimilar for Humira, supporting Organon's biosimilars pipeline.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching HUMIRA
Events traced to HUMIRA, step by step, newest firstAround HUMIRA this week
News at the entities that move HUMIRA most-
Bristol-Myers Squibb StructuralAstraZeneca sought a mega-merger with a US rival, adding a specific development to the ongoing talks with Bristol-Myers Squibb.Moves HUMIRA
-
Alvotech OperationalBank of America started coverage and Barclays raised its rating and target price for Alvotech.Moves HUMIRA
-
Medicare OperationalMedia is covering US political and tax policy, including discussions about the Medicare bonus and IRS material.Moves HUMIRA
-
Eli Lilly and Company OperationalCRISPR Therapeutics, Eli Lilly, and Johnson & Johnson are noted as major holdings in health care ETFs.Moves HUMIRA
-
AbbVie StructuralEarnings reports are in focus for AbbVie, ExxonMobil, and Amazon, coinciding with a rebound in oil prices.Moves HUMIRA
-
Europe Shared contextMohawk Industries noted soft demand in Europe, while Paul De Cock emphasized the company's performance.Moves HUMIRA
Connections
The 8 strongest of 22, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
AbbVie Structural
AbbVie's financial health and corporate strategy were historically defined by the market lifecycle and patent status of its flagship drug, Humira.
-
Bristol-Myers Squibb Structural
The company utilizes the product as a core part of its therapeutic offerings, which are currently facing market pressures from biosimilar competition.
-
Alvotech Operational
Alvotech is developing a biosimilar product intended to compete directly with Humira in the market.
-
Eli Lilly and Company Operational
The relationship is characterized by market competition, where Eli Lilly's growth offsets the decline of Humira.
-
Vanderbilt University School of Medicine Shared context
The entities share a relevant research/market context as biosimilar drugs targeting the same conditions as Humira.
-
Harvard Medical School Mentioned together
HMS researchers are studying the biosimilar competition and generic market dynamics surrounding the drug HUMIRA.
-
Medicare Operational
Medicare operates in a market where generic and biosimilar competition drives down prices, affecting HUMIRA's competitive landscape.
-
Europe Shared context
Humira's patent protection was lost in Europe.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
1 eventJune 2026
12 events- AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.
- AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.
- AbbVie's Humira is losing exclusivity and facing intense competition from Skyrizi and Rinvoq.
- AbbVie products are succeeding Humira in the market, while FDA approvals and Fed caution influence market expectations.
- Declining sales of Humira due to biosimilar erosion.
- Lost patent protection for Humira in the US on August 20, 2025.
- cAMPfield Therapeutics is seeking alternatives to drugs like Humira, while Blackstone invests in drug development deals.
- The patent expiry of Humira is weighing on sentiment, influenced by geopolitical uncertainty in the Middle East.
- AbbVie, which lost exclusivity for Humira, is facing potential tariffs on pharmaceutical imports from the Trump administration.
- Johnson & Johnson tested nipocalimab against Humira, while Amgen is noted for biosimilar competition in the market for Humira.
- MoonLake Immunotherapeutics' sonelokimab demonstrated superior performance compared to Humira in multiple Psoriasis metrics.
- FDA recognized Hadlima as an interchangeable biosimilar for Humira, supporting Organon's biosimilars pipeline.